Eli Lilly reports third-quarter results this morning before the open, and the numbers arriving alongside the 10 a.m. EDT conference call carry more strategic weight than a typical earnings release. The company is expected to post revenue of about $22.61 billion, which would represent growth of roughly 28% from a year earlier. But the revenue line is almost secondary to what it implies: Lilly has been running an aggressive comparative advertising campaign against Novo Nordisk for months, and this is the first quarter where the market-share consequences are visible in actual prescription data.
The Bull Case
Start with the drugs themselves. Analysts treat Mounjaro and Zepbound as the main drivers, with Mounjaro projected at about $10.04 billion and Zepbound contributing roughly $5.03 billion, together accounting for nearly two-thirds of expected revenue. Those are not the numbers of a company losing ground to a rival.
The advertising dispute reinforces that reading. Lilly won an early judicial battle in its dispute with Novo Nordisk when a U.S. judge rejected Novo’s bid to temporarily prohibit Lilly from advertising Zepbound and Mounjaro. U.S. District Judge Zahid Quraishi rejected that request, calling Novo’s showing “inadequate to warrant the extraordinary relief it seeks.” The commercials stay on air, and Lilly enters earnings day with its marketing firepower intact.
Beyond the injectable franchise, Lilly now has an oral card to play. The FDA approved orforglipron, branded as Foundayo, for chronic weight management. In diabetes, Lilly has also pointed to ACHIEVE-3 data showing orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints. That is a direct competitive advantage over Novo’s Rybelsus on convenience, since orforglipron has no food or water restrictions. Early Foundayo demand figures in today’s report could be a meaningful upside catalyst that the Street has not fully modeled.
The forward picture supports the optimism. Analysts estimate full-year 2026 revenue at about $88.6 billion, implying roughly 36% annual growth. At those growth rates, the bull argument is that Lilly is still in the early innings of GLP-1 market expansion.
The Bear Case
The problem is the price. Shares closed at $1,281.91 on Tuesday, giving Lilly a market cap above $1 trillion. The stock has climbed roughly 55% over the past year. At those levels, the valuation demands continuous beats, not merely strong execution.
The valuation pressure on Lilly is not only about execution risk inside its own pipeline. Viking Therapeutics is showing Phase 2 efficacy numbers comparable to tirzepatide, with monthly maintenance dosing that neither Zepbound nor Wegovy has established in a trial.
The EPS picture heading into today is genuinely complicated. The Q3 EPS consensus has slid to around $6.67 from higher levels recently, a move that commentary has tied largely to acquired in-process R&D charges and other items around deal activity. The year-ago comparable sits at $7.02. Any miss against a sharply reduced bar would land poorly on a stock priced for perpetual outperformance.
The advertising win also deserves a careful read. In denying Novo’s request for preliminary injunctive relief, the court pointed to evidence that Novo’s prescriptions remained steady, which undercuts the claim of irreparable harm from the ads. Lilly’s campaign generated enormous reach, with Novo alleging about 700 million impressions since April 2026, but if today’s Zepbound revenue comes in below the $5 billion threshold, the argument that the campaign is actually converting patients weakens considerably. The advertising war looks like a win on paper; today’s numbers decide whether it was a win in the pharmacy.
Where the Evidence Leads
The bull case rests on durable facts: head-to-head clinical results in diabetes, a court-cleared marketing platform, and a newly approved oral product that Novo cannot currently match on convenience. These are structural advantages, not projections.
The oral approval also reshapes the addressable market in ways the injectable revenue figures alone do not capture. Foundayo’s no-food-restriction design targets the roughly nine in ten eligible patients who have never started any GLP-1 therapy.
The bear case rests on one uncomfortable arithmetic reality. Even at a forward P/E closer to the high 30s on revised full-year estimates, Lilly is priced for a future that has to arrive on schedule, every quarter. A guidance cut, a Foundayo launch that underwhelms, or any signal that Novo’s higher-dose Wegovy HD is stabilizing share would force investors to reassess the multiple sharply.
Final Verdict
The evidence tilts bullish on the business, cautious on the stock. Lilly’s competitive position in GLP-1 is stronger today than six months ago: a favored injectable franchise, a court-cleared ad campaign, and an FDA-approved oral drug that beat its only oral rival head-to-head in diabetes. That is a formidable hand. The reservation is not about the company; it is about the margin for error at roughly $1,282 per share. Today’s report needs to confirm that the advertising campaign is moving prescriptions, not just impressions. If Mounjaro clears $10 billion and Foundayo shows early traction, Lilly’s valuation becomes easier to defend. If either disappoints, the stock’s premium can evaporate quickly.
